Pharmacogenetic impact of UGT1A1 polymorphisms on pulmonary neuroendocrine tumours treated with metronomic irinotecan‐based chemotherapy in Chinese populations

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Metronomic Chemotherapy: A Systematic Review of the Literature and Clinical Experience

(2019) Cem Simsek et al.   Journal of Oncology

Dose optimization of tacrolimus with therapeutic drug monitoring and CYP3A5 polymorphism in patients with myasthenia gravis

(2018) D. Chen et al.   EUROPEAN JOURNAL OF NEUROLOGY

Cancer statistics in China, 2015

(2016) Wanqing Chen et al.   CA-A CANCER JOURNAL FOR CLINICIANS

UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer

(2016) Chunlei Xu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Correlation of UGT1A1 * 28 and * 6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients

(2016) Chalirmporn Atasilp et al.   Drug Metabolism and Pharmacokinetics

Genotype ofUGT1A1and phenotype correlation between Crigler-Najjar syndrome type II and Gilbert syndrome

(2016) Yoshihiro Maruo et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial

(2016) Koichi Goto et al.   LANCET ONCOLOGY

Association between UGT1A1*28 Polymorphisms and Clinical Outcomes of Irinotecan-Based Chemotherapies in Colorectal Cancer: A Meta-Analysis in Caucasians

(2013) Xiang Liu et al.   PLoS One

Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur–gimeracil–oteracil potassium in metastatic and recurrent breast cancer

(2013) Hiroko Otsuka et al.   Breast Cancer

UGT1A1predicts outcome in colorectal cancer treated with irinotecan and fluorouracil

(2012) Yan Wang   WORLD JOURNAL OF GASTROENTEROLOGY

Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results

(2010) S. R. Park et al.   ANNALS OF ONCOLOGY

Combined effect of regulatory polymorphisms on transcription of UGT1A1 as a cause of Gilbert syndrome

(2010) Katsuyuki Matsui et al.   BMC GASTROENTEROLOGY

A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn)

(2009) Zhiqiang Li et al.   CELL RESEARCH

UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients

(2009) Masahide Onoue et al.   International Journal of Clinical Oncology

UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer

(2009) Christoph Schulz et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes

(2008) J. M. Hoskins et al.   CLINICAL CANCER RESEARCH